Solid Biosciences (NASDAQ:SLDB) Trading Up 9.9%
Solid Biosciences Inc (NASDAQ:SLDB)’s stock price was up 9.9% during mid-day trading on Monday . The stock traded as high as $4.55 and last traded at $4.32, approximately 1,235,027 shares traded hands during mid-day trading. An increase of 71% from the average daily volume of 723,323 shares. The stock had previously closed at $3.93.
Several research analysts have recently issued reports on SLDB shares. Leerink Swann upgraded Solid Biosciences from a “market perform” rating to an “outperform” rating in a research note on Monday, August 19th. Zacks Investment Research cut Solid Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 16th. Chardan Capital upgraded Solid Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $7.50 to $10.00 in a research note on Friday, August 16th. Svb Leerink upgraded Solid Biosciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $8.00 to $15.00 in a research note on Monday, August 19th. Finally, Credit Suisse Group reduced their price target on Solid Biosciences from $6.00 to $2.00 and set a “hold” rating for the company in a research report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $8.93.
The firm has a 50-day moving average of $8.68 and a two-hundred day moving average of $7.43. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $180.73 million, a PE ratio of -1.92 and a beta of 1.38.
Solid Biosciences Company Profile (NASDAQ:SLDB)
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Recommended Story: Net Income
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.